Comparative Pharmacology
Head-to-head clinical analysis: KETEK versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETEK versus SATRIC.
KETEK vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Telithromycin 800 mg orally once daily for 7-10 days.
No standard dosing information available for SATRIC.
None Documented
None Documented
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category C
Category C
Antibiotic, Ketolide
Antiprotozoal, Antibiotic